Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update

Intravenous vernakalant has recently been approved in Europe as an atrial-selective antiarrhythmic drug for the conversion of recent-onset atrial fibrillation (AF). It inhibits atrial-selective K(+) currents (I(K,ACh) and I(Kur)) and causes rate-dependent atrial-predominant Na(+) channel block, with...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsuji, Yukiomi, Dobrev, Dobromir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639220/
https://www.ncbi.nlm.nih.gov/pubmed/23637539
http://dx.doi.org/10.2147/VHRM.S43720

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3639220/
https://www.ncbi.nlm.nih.gov/pubmed/23637539
http://dx.doi.org/10.2147/VHRM.S43720

Ejemplares similares